Cancer immunotherapy represents a promising strategy for improving cancer treatment outcomes. As a result, numerous preclinical and clinical studies using different types of therapeutic vaccines are ongoing. (1)
Read our white paper “Targeted skin drug delivery: a new era in cancer therapy?” to find out why intradermal vaccine delivery is capable of improving the immune response .
Unfortunately, the current standard of care for intradermal injection (the Mantoux technique) is difficult to perform and prone to failure. (2)
Furthermore, discover why VAX-ID®, an accurate and reliable intradermal drug delivery device, offers a potential game-changing solution for intradermal delivery of therapeutic vaccines and cells.